Immunity is partly destroyed by the effects of high-dose chemotherapy associated with hematopoietic stem cell transplantation. A new strategy restores impaired immunity in people and offers clues to improving vaccination against pathogens and tumors (pages 1230–1237).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rapoport, A.P. et al. Nat. Med. 11, 1230–1237 (2005)
Storek, J. et al. Blood 101, 3319–3324 (2003).
Fry, T.J. & Mackall, C.L. Bone Marrow Transplant. 35 Suppl 1, S53–S57 (2005).
Goldrath, A.W. & Bevan, M.J. Immunity 11, 183–190 (1999).
Liebowitz, D.N., Lee, K.P. & June, C.H. Curr. Opin. Oncol. 10, 533–541 (1998).
Molldrem, J.J. et al. J. Clin. Invest. 111, 639–647 (2003).
Fry, T.J. et al. Blood 97, 1525–1533 (2001).
Mackall, C.L., Hakim, F.T. & Gress, R.E. Immunol. Today 18, 245–251 (1997).
Watanabe, N. et al. Nat. Immunol. 5, 426–434 (2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Molldrem, J. Vaccinating transplant recipients. Nat Med 11, 1162–1163 (2005). https://doi.org/10.1038/nm1105-1162
Issue Date:
DOI: https://doi.org/10.1038/nm1105-1162
This article is cited by
-
From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation
Current HIV/AIDS Reports (2020)
-
Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of γ-interferon
Bone Marrow Transplantation (2007)
